Multiple Sclerosis | Current Treatment | US | 2016
Multiple sclerosis (MS) is a dynamic therapy market in the United States with 12 branded (and 1 generic) disease-modifying therapies (DMTs) boasting unique balances of efficacy, safety, and convenience. In just the past five years, six new MS DMTs have launched—one infusion, three injectable, and two oral—drastically altering physician prescribing practices and preferences. The Multiple Sclerosis | Current Treatment overview provides a synopsis of current treatment goals, key therapies, and medical practice in the G7 markets, while the Multiple Sclerosis | Current Treatment | US presents a snapshot of how U.S. neurologists are prescribing current DMTs and insight into the factors driving their prescribing habits.
Related Market Assessment Reports
Report
Gene Therapy – Access & Reimbursement – Access & Reimbursement – Gene Therapies for Rare Diseases (US)
With the increasing number of approved innovative, high-cost gene therapies, value assessment and novel reimbursement approaches are rapidly gaining importance. To assist developers of gene…
Report
Hidradenitis Suppurativa – Current Treatment – Treatment Algorithms: Claims Data Analysis – Hidradenitis Suppurativa (US)
Hidradenitis suppurativa (HS) is a chronic, relapsing inflammatory disorder of the hair follicles, characterized by painful, inflamed lesions often filled with fluid or pus. AbbVie’s Humira (…
Report
Squamous Cell Carcinoma of the Head and Neck – Landscape & Forecast – Disease Landscape & Forecast (Major Markets)
Squamous cell carcinoma of the head and neck (SCCHN) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and…
Report
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (US)
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAAD) is a rare autoimmune inflammatory CNS disorder defined by IgG antibodies targeting the myelin oligodendrocyte glycoprotein…
